Подписаться
Yuriy Mostovoy Юрій Мостовой
Yuriy Mostovoy Юрій Мостовой
National Pirogov Memorial Medical University, Vinnytsya Вінницький національний медичний університет
Подтвержден адрес электронной почты в домене vnmu.edu.ua - Главная страница
Название
Процитировано
Процитировано
Год
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
K Swedberg, M Komajda, M Böhm, JS Borer, I Ford, A Dubost-Brama, ...
The Lancet 376 (9744), 875-885, 2010
33202010
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
WB White, CP Cannon, SR Heller, SE Nissen, RM Bergenstal, GL Bakris, ...
New England journal of medicine 369 (14), 1327-1335, 2013
30942013
Alirocumab and cardiovascular outcomes after acute coronary syndrome
GG Schwartz, PG Steg, M Szarek, DL Bhatt, VA Bittner, R Diaz, ...
New England Journal of Medicine 379 (22), 2097-2107, 2018
26222018
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial
K Fox, I Ford, PG Steg, M Tendera, R Ferrari
The Lancet 372 (9641), 807-816, 2008
14632008
Ivabradine in stable coronary artery disease without clinical heart failure
K Fox, I Ford, PG Steg, JC Tardif, M Tendera, R Ferrari
New England Journal of Medicine 371 (12), 1091-1099, 2014
6192014
Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial
J Vestbo, JA Anderson, RD Brook, PMA Calverley, BR Celli, C Crim, ...
The Lancet 387 (10030), 1817-1826, 2016
4872016
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
WW Busse, ER Bleecker, JM FitzGerald, GT Ferguson, P Barker, ...
The lancet respiratory medicine 7 (1), 46-59, 2019
2842019
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY …
KK Ray, HM Colhoun, M Szarek, M Baccara-Dinet, DL Bhatt, VA Bittner, ...
The lancet Diabetes & endocrinology 7 (8), 618-628, 2019
2462019
FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia
DE Low, TM File Jr, PB Eckburg, GH Talbot, H David Friedland, J Lee, ...
Journal of antimicrobial chemotherapy 66 (suppl_3), iii33-iii44, 2011
2152011
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study
ME Wechsler, A Menzies-Gow, CE Brightling, P Kuna, S Korn, T Welte, ...
The Lancet Respiratory Medicine 10 (7), 650-660, 2022
1142022
Процедура адаптації міжнародного опитувальника оцінки якості життя MOS SF-36 в Україні. Досвід застосування у хворих бронхіальною астмою
ЮІ Фещенко, ЮМ Мостовой, ЮВ Бабійчук
Український пульмонологічний журнал 3, 9-11, 2002
1022002
Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation
GYH Lip, SK Rushton-Smith, SZ Goldhaber, DA Fitzmaurice, ...
Circulation: Cardiovascular Quality and Outcomes 8 (2_suppl_1), S12-S20, 2015
952015
Fenebrutinib versus placebo or Adalimumab in rheumatoid arthritis: A randomized, Double‐Blind, phase II trial
S Cohen, K Tuckwell, TR Katsumoto, R Zhao, J Galanter, C Lee, J Rae, ...
Arthritis & Rheumatology 72 (9), 1435-1446, 2020
902020
Early risks of death, stroke/systemic embolism, and major bleeding in patients with newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry
JP Bassand, S Virdone, SZ Goldhaber, AJ Camm, DA Fitzmaurice, ...
Circulation 139 (6), 787-798, 2019
86*2019
Хронічне обструктивне захворювання легень
ЮІ Фещенко, ВК Гаврисюк, ОЯ Дзюблик, ЮМ Мостовой, НД Чухрієнко, ...
Здор. Укр.–2014.–8 (333).–С.–50–51, 2001
862001
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials
DT Rubin, I Dotan, A DuVall, Y Bouhnik, G Radford-Smith, PDR Higgins, ...
The lancet Gastroenterology & hepatology 7 (1), 17-27, 2022
702022
Госпітальна пневмонія у дорослих осіб: етіологія, патогенез, класифікація, діагностика, антибактеріальна терапія (проект клінічних настанов) частина ІІ
ЮІ Фещенко, ОА Голубовська, КА Гончаров, ОЯ Дзюблик, ЯО Дзюблик, ...
Український пульмонологічний журнал, 5-18, 2013
622013
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt …
HJL Heerspink, D Cherney, D Postmus, BV Stefánsson, GM Chertow, ...
Kidney international 101 (1), 174-184, 2022
612022
Management and 1‐year outcomes of patients with newly diagnosed atrial fibrillation and chronic kidney disease: results from the prospective GARFIELD‐AF registry
S Goto, P Angchaisuksiri, JP Bassand, AJ Camm, H Dominguez, ...
Journal of the American Heart Association 8 (3), e010510, 2019
612019
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials
JR Teerlink, R Diaz, GM Felker, JJV McMurray, M Metra, SD Solomon, ...
European journal of heart failure 22 (11), 2160-2171, 2020
552020
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20